GMO Financial grew revenue while disclosed OTC-FX volume fell 18.8%

GMO Financial Holdings increased nine-month operating revenue and profit in 2026 even though the combined disclosed over-the-counter foreign-exchange trading value of its two named platforms fell by almost one-fifth. FXBrokers.ai summed the January-to-September monthly figures for FX Neo and GMO Gaika from the company’s own operating-data archive. The combined total fell from 23,361,977 to 18,967,435 in the published unit of ¥100 million, a decline of 18.81%. Over the same period, group operating revenue rose 15.9% to ¥44.507 billion and operating profit rose 17.3% to ¥16.065 billion.[1][2][3]

The divergence is not evidence that the volume data or the financial statements are inconsistent. It demonstrates that disclosed OTC-FX turnover is not the same thing as group revenue. A financial group can earn more with lower FX notional if product mix, spreads, volatility, financial income, customer margin utilisation, CFDs or other businesses improve. GMO’s own results explanation points in that direction: it said nine-month OTC-FX revenue remained below the prior-year period because of weakness in the first half, while third-quarter FX profitability improved; CFD revenue remained well above the prior year; and income linked to customer margin deposits and margin trading supported financial revenue.[1][3][4]

The volume calculation

FX Neo accounted for most of the decline. Its nine-month sum fell by 3,749,732 units, or 19.69%. GMO Gaika fell by 644,810 units, or 14.93%. The combined reduction was 4,394,542 units in the source’s ¥100 million convention. Because the numbers are enormous, converting them casually into yen or trillions can introduce errors. The cleanest comparison is to preserve the published unit and use the same nine months for both years. That is what the 18.81% calculation does.[2]

The financial comparison uses the same January-to-September period. Operating revenue rose from ¥38.413 billion to ¥44.507 billion, an increase of 15.86%. Net operating revenue rose 14.4% to ¥40.677 billion. Operating profit rose from ¥13.691 billion to ¥16.065 billion, an increase of 17.34%. Ordinary profit rose 24.4% and profit attributable to owners rose 18.2%. The group therefore produced record nine-month results even though its disclosed OTC-FX turnover was materially below the previous year.[1][3]

Why volume and revenue can move in opposite directions

Notional volume is a scale measure, not a revenue measure. Revenue depends on the economics attached to that volume: spread capture, hedging results, the proportion of internalised and externally hedged flow, instrument mix, customer behaviour and volatility. A lower-value mix can be more profitable than a higher-volume one, and a larger notional can produce weak revenue if competition compresses spreads or market conditions reduce capture. The monthly archive does not provide the revenue earned per unit of FX turnover, so it cannot support a direct take-rate calculation.[2][4]

The group is also broader than OTC FX. GMO said CFD revenue, although below a record first quarter, remained substantially above the corresponding 2025 period and drove overall earnings. It also cited continued growth in financial revenue from the utilisation of customer margin deposits and margin trading. Crypto-asset revenue declined against a softer market, which shows that diversification did not make every business line favourable. The aggregate result reflects the net effect of several products and balance-sheet income streams, not a one-for-one conversion of FX volume.[3][4]

The third quarter provides a timing explanation inside the nine-month total. The company said foreign-exchange volatility increased amid coordinated Japan–US currency intervention and comments aimed at restraining yen weakness, significantly improving FX profitability and narrowing the year-on-year revenue decline. That means the weak first-half comparison and stronger third-quarter economics coexist inside the same cumulative period. A nine-month volume total cannot reveal this change in profitability without monthly or quarterly revenue detail by product.[3][4]

The data boundary is narrower than the group

The 18.81% figure should not be described as a fall in all GMO group FX activity. It is the sum of two public monthly series — FX Neo and GMO Gaika — that the company identifies in its archive. Other products, legal entities, institutional flows or internal accounting measures may not be represented. Nor should the combined total be used as a customer-loss measure: trading value records notional activity, not gains, losses, deposits or net customer positions. The investigation’s conclusion survives these limits because it compares the same two series across the same months in each year.[2]

The archive also labels monthly indicators as preliminary and subject to revision. That is important for auditability. A later correction to one month could alter the aggregate, although a modest revision would not erase a decline of almost 19%. The calculation should nevertheless be refreshed before publication or when the company revises its archive. Preserving the underlying monthly inputs makes that possible; relying only on a derived percentage would not.[2]

A diversification signal, not a take-rate claim

The evidence strongly indicates that group earnings in 2026 were less dependent on sheer disclosed OTC-FX turnover than a volume-only reading would suggest. It does not prove that the OTC-FX take rate increased, because product-level revenue and the relevant transaction-cost denominator are not disclosed in a form that allows that calculation. The company itself said cumulative OTC-FX revenue remained lower year on year, which argues against claiming that lower volume was fully offset by better FX monetisation. The group-level improvement came from a combination that included third-quarter FX profitability, CFDs and financial revenue.[1][3][4]

That distinction matters for competitors and investors. A broker can report impressive notional turnover while producing poor economics, and another can report lower turnover while generating higher group profit through a different product mix. Rankings based solely on volume can therefore misstate commercial strength. Conversely, group profit growth should not be used to imply that the core FX franchise grew. GMO’s own explanation says the opposite for cumulative OTC-FX revenue. The accurate account is a divergence: lower public FX volume and FX revenue, but higher group revenue and profit.[1][2][3]

What would complete the reconstruction

A full bridge would disclose OTC-FX revenue by quarter, average spread or revenue per trillion yen of turnover, hedge and liquidity costs, the contribution of financial income linked to customer balances, and CFD revenue on a comparable basis. That would allow analysts to separate activity, pricing, risk management and balance-sheet yield. Product-level customer-account and margin-balance data would also show whether the group’s improved financial revenue came from larger balances, higher yields or both.[1][3]

The present calculation is still consequential because it replaces a vague diversification claim with an independently reproducible scale comparison. The two disclosed OTC-FX series fell 18.81% over the first nine months. Operating revenue rose 15.86%, and operating profit rose 17.34%. The company’s narrative confirms that cumulative OTC-FX revenue was lower while CFDs and financial revenue supported results. These sources converge on the same conclusion: GMO’s record group performance was not driven by higher disclosed FX turnover.[1][2][3][4]

Future data can test whether this was temporary or structural. If FX volume recovers and group profit rises further, 2026 may look like a transitional period in which other earnings streams carried the group. If volume remains lower while profitability stays high, the case for a more diversified and less volume-dependent model will strengthen. If CFD or financial revenue weakens, the group’s exposure to the FX cycle may re-emerge. For now, the evidence supports a precise statement: nine-month disclosed OTC-FX value fell by almost one-fifth while the consolidated top and bottom lines grew.[1][2][3]

The reconstruction also rules out one common shortcut: dividing consolidated operating revenue by the two disclosed FX-volume series and calling the result a group take rate. The numerator includes businesses and products outside those platforms, while the denominator excludes activity not shown in the same monthly archive. Such a ratio would manufacture precision from mismatched perimeters. The correct next step is a product bridge showing FX spreads and fees, CFD and securities revenue, customer balances and any market-making result against matched volumes. Until then, the divergence is evidence of changing earnings mix, not proof that GMO earned more on every unit of OTC-FX turnover.[1][2][3][4]

That matched disclosure would determine whether the divergence reflects pricing, product diversification, balance-sheet income or a reporting-perimeter change.[1][2][3][4]

Report an error or submit an update